Cargando…

A NOVEL MSLN×4-1BB BISPECIFIC ANTIBODY FOR SOLID TUMOR

BACKGROUND: Mesothelin (MSLN) is a 70 KD glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein that is rarely expressed in normal tissues but overexpressed in a variety of cancers, including mesothelioma, ovarian cancer, pancreatic cancer and breast cancer et.al. 4-1BB is a member of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Liansheng, Zhang, Dayan, Liu, Wenting, Zhou, Weiming, Zeng, Xiaoli, Zhao, Qun, Shen, Guodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370454/ http://dx.doi.org/10.1093/abt/tbad014.003

Ejemplares similares

An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity
por: Cheng, Lian-sheng, et al.
Publicado: (2023)

Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
por: Liguori, Luigi, et al.
Publicado: (2022)

Recent advances of bispecific antibodies in solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017)

A BIVALENT TIM-3/PD-1 BISPECIFIC ANTIBODY FOR THE TREATMENT OF PD-1 ANTIBODY RESISTANT OR REFRACTORY SOLID TUMORS
por: Luan, Yan, et al.
Publicado: (2023)

A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity
por: Cheng, Lian-sheng, et al.
Publicado: (2022)

Recent advances and challenges of bispecific antibodies in solid tumors
por: Wu, Yuze, et al.
Publicado: (2021)

A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy
por: Zeng, Wuyi, et al.
Publicado: (2022)

A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
por: Yoon, Aerin, et al.
Publicado: (2020)

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
por: Middelburg, Jim, et al.
Publicado: (2021)

OVERCOMING TECHNICAL CHALLENGES OF BISPECIFIC AND MULTI-SPECIFIC ANTIBODIES USING NOVEL TECHNOLOGY PLATFORMS
por: Xu, Jianqing, et al.
Publicado: (2023)

HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients
por: Tegeler, Christian M., et al.
Publicado: (2022)

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
por: Jeong, Seongju, et al.
Publicado: (2021)

Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality
por: Schoutrop, Esther, et al.
Publicado: (2022)

PRELIMINARY SAFETY, EFFICACY AND PHARMACOKINETICS (PK) RESULTS OF KN026 (A HER2 BISPECIFIC ANTIBODY) MONOTHERAPY IN ADVANCED SOLID TUMOR PATIENTS WITH HER2 EXPRESSION
por: Xu, Ting, et al.
Publicado: (2023)

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
por: Muik, Alexander, et al.
Publicado: (2022)

A NOVEL IMMUNOSTIMULATORY PD-L1/OX40 TETRAVALENT BISPECIFIC ANTIBODY FOR CANCER IMMUNOTHERAPY
por: Li, Baocun, et al.
Publicado: (2023)

A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer
por: Deng, Li, et al.
Publicado: (2012)

MSLN Correlates With Immune Infiltration and Chemoresistance as a Prognostic Biomarker in Ovarian Cancer
por: Li, Yike, et al.
Publicado: (2022)

An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation
por: Muik, Alexander, et al.
Publicado: (2022)

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
por: Antonarelli, Gabriele, et al.
Publicado: (2021)

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
por: Gao, Jing, et al.
Publicado: (2023)

YEAST SURFACE DISPLAY OF FULL-LENGTH IGG FOR ENGINEERING MONOCLONAL AND BISPECIFIC ANTIBODIES
por: Jiang, Youwei
Publicado: (2023)

Evaluation of Soluble Mesothelin-related Peptides and MSLN Genetic Variability in Asbestos-related Diseases
por: Goricar, Katja, et al.
Publicado: (2020)

Effects of hsa-mir-145-5p on the Regulation of msln Expression in Colorectal Adenocarcinoma
por: Li, Junhua, et al.
Publicado: (2022)

A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer
por: Sun, Zu-Jun, et al.
Publicado: (2017)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
por: Bacac, Marina, et al.
Publicado: (2016)

Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors
por: Root, Adam R., et al.
Publicado: (2021)

B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8(+) tumor-infiltrating lymphocytes
por: You, Gihoon, et al.
Publicado: (2021)

Fully human antibody V(H) domains to generate mono and bispecific CAR to target solid tumors
por: Wang, Guanmeng, et al.
Publicado: (2021)

Clinical safety and efficacy of bispecific antibody in the treatment of solid tumors: A protocol for a systematic review
por: Nejadghaderi, Seyed Aria, et al.
Publicado: (2022)

Structural basis of a novel heterodimeric Fc for bispecific antibody production
por: Wei, Hudie, et al.
Publicado: (2017)

Tandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer
por: Liang, Zhen, et al.
Publicado: (2021)

Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
por: Schoutrop, Esther, et al.
Publicado: (2023)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
por: Jiang, Haiping, et al.
Publicado: (2021)

The development of bispecific antibodies and their applications in tumor immune escape
por: Zhang, Xiaolong, et al.
Publicado: (2017)

Bispecific Antibodies: From Research to Clinical Application
por: Ma, Jiabing, et al.
Publicado: (2021)

Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
por: Simão, Diana C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1bpdulr2a2roo130f2d7ubv4cn